Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of “Buy” from Brokerages

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating) has been assigned a consensus rating of “Buy” from the fifteen brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, ten have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $70.67.

A number of analysts recently weighed in on APLS shares. Citigroup restated a “focus list” rating and issued a $81.00 target price on shares of Apellis Pharmaceuticals in a research report on Thursday, March 17th. Roth Capital downgraded Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $40.00 target price for the company. in a research report on Wednesday, April 13th. JPMorgan Chase & Co. boosted their target price on Apellis Pharmaceuticals from $66.00 to $69.00 and gave the stock an “overweight” rating in a research report on Monday, April 4th. Raymond James boosted their price objective on Apellis Pharmaceuticals from $112.00 to $114.00 and gave the company a “strong-buy” rating in a research report on Tuesday, March 1st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $70.00 price objective on shares of Apellis Pharmaceuticals in a research report on Friday, December 31st.

Shares of APLS opened at $52.86 on Thursday. The stock has a 50-day moving average price of $48.47 and a 200-day moving average price of $43.17. The company has a market cap of $5.61 billion, a PE ratio of -5.92 and a beta of 1.61. Apellis Pharmaceuticals has a 12-month low of $27.50 and a 12-month high of $73.00. The company has a current ratio of 6.25, a quick ratio of 6.13 and a debt-to-equity ratio of 0.95.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last released its earnings results on Monday, February 28th. The company reported ($1.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.54) by ($0.07). During the same period in the prior year, the company posted $0.93 earnings per share. As a group, analysts predict that Apellis Pharmaceuticals will post -5.26 earnings per share for the current year.

In related news, Director Alec Machiels sold 1,250 shares of the company’s stock in a transaction on Tuesday, March 15th. The stock was sold at an average price of $39.57, for a total value of $49,462.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Lukas Scheibler sold 3,504 shares of the company’s stock in a transaction on Monday, April 4th. The stock was sold at an average price of $56.96, for a total value of $199,587.84. Following the completion of the sale, the insider now directly owns 52,233 shares in the company, valued at $2,975,191.68. The disclosure for this sale can be found here. Insiders have sold 32,399 shares of company stock worth $1,609,595 over the last three months. Insiders own 9.50% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Oppenheimer Asset Management Inc. bought a new stake in Apellis Pharmaceuticals in the third quarter worth $54,000. Harbor Investment Advisory LLC boosted its holdings in Apellis Pharmaceuticals by 25.1% in the fourth quarter. Harbor Investment Advisory LLC now owns 1,267 shares of the company’s stock worth $60,000 after acquiring an additional 254 shares in the last quarter. Meeder Asset Management Inc. boosted its holdings in Apellis Pharmaceuticals by 56.8% in the third quarter. Meeder Asset Management Inc. now owns 2,628 shares of the company’s stock worth $87,000 after acquiring an additional 952 shares in the last quarter. O Shaughnessy Asset Management LLC boosted its holdings in Apellis Pharmaceuticals by 21.7% in the third quarter. O Shaughnessy Asset Management LLC now owns 3,006 shares of the company’s stock worth $99,000 after acquiring an additional 537 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its holdings in Apellis Pharmaceuticals by 80.8% in the third quarter. Advisor Group Holdings Inc. now owns 4,001 shares of the company’s stock worth $132,000 after acquiring an additional 1,788 shares in the last quarter. 82.03% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile (Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Read More

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.